26 Oct 2018

Researchers from Queen’s University Belfast and the University of Leeds, as part of a pan-European partnership called the European Cancer Concord (ECC) ®, have won the prestigious 2018 European Health Award.

This award honours initiatives that help tackle some of Europe’s most pressing health challenges.


The award-winning project, entitled ‘The European Cancer Patient’s Bill of Rights: A Catalyst for Change and an empowerment tool for cancer patients across Europe’ involves an equal partnership between cancer patients, healthcare professionals and cancer researchers.

Professor Mark Lawler, Vice President of the European Cancer Concord (ECC), today received the award on behalf of ECCO during the opening ceremony of the European Health Forum Gastein, the premier European Health Policy Conference and an official event of the Austrian European Council Presidency. 

25 Jul 2018

Susan Richman from the Leeds Institute of Cancer and Pathology obtained £1120 from the Medical Research Council (MRC)  to fund a stand  at the MRC’s Festival of Medical Research.  The stand titled, ‘So, just what is personalised Medicine?’ was split into three sections, with the first aiming to bust the stigma around bowel cancer screening, incorporating a game and a competition.



S:CORT is a consortium jointly funded by Cancer Research UK (CRUK) and the Medical Research Council (MRC) to help personalise colorectal (bowel) cancer treatment by matching patients to the most effective therapies.


Our consortium is a collaboration between Academic, Industry, Charity and Patient Group Partners:

Academic Partners:

University of Oxford

Queen’s University Belfast

University of Birmingham

University of Leeds

Wellcome Trust Sanger Institute

MRC Clinical Trials Unit - UCL

Kings College London;

University of Aberdeen


Industry Partners:

Almac Diagnostics

About Almac Diagnostics:

Almac Diagnostics is a personalised medicine company focused on the discovery, development and commercialisation of diagnostic and companion diagnostic tests. These tests are aimed to guide patient treatment decisions which will ultimately improve care in a wide range of disease areas including colon cancer.


Strategic Partnerships:

Bowel Cancer UK

Northern Ireland Cancer Research Consumer Forum

European Organisation for Research and Treatment of Cancer

European Alliance for Personalised Medicine

European CanCer Organisation


  • Oxford University King's College London Queen's University Belfast
  • University of Leeds University of Aberdeen Sanger Institute
  • University College London University of Birmingham Partnering to Advance Human Health